A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes

NCT06894784 on ClinicalTrials.gov · last registry update 2025-03-30

A small phase 3 — 36 participants, against a typical 424. Due to report January 2027, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: Time-in-Range. Sponsors move these dates routinely; any movement since this site started watching is listed below.

Status: RECRUITING
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Sponsor type: Other
Enrollment: 36
Started: 2025-04
Primary completion: 2027-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Time-in-Range

Conditions studied

Diabetes Type 1

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.